Spineart received Investigational Device Exemption (IDE) approval from FDA to initiate a clinical trial of the BAGUERA® C Cervical Disc Prosthesis. The single-level trial compares BAGUERA C to another FDA approved arthroplasty device at up to 30 centers across the U.S.
BAGUERA C is an MRI compatible disc. Anatomically shaped endplates accommodate patient anatomy and minimize vertebral endplate manipulation. The inner layers of the endplates feature a diamond-like-coating to minimize wear. A load sharing design and the guided mobile nucleus are intended to prevent excessive constraints on the facet joints and adjacent levels.
In 2016, two-year study results indicated that patients treated with the BAGUERA C cervical disc in 1- or 2-level arthroplasty exhibited good mobility at treated and adjacent levels, disc height restoration and evidence of adjacent level preservation.
Jerome Trividic, President of Spineart USA, said, “Thanks to a fruitful collaboration with the FDA, we will be starting patient enrollment in the upcoming months. We are excited to bring BAGUERA C to the United States, after more than a decade of successful patient outcomes outside the U.S.”
Spineart received Investigational Device Exemption (IDE) approval from FDA to initiate a clinical trial of the BAGUERA® C Cervical Disc Prosthesis. The single-level trial compares BAGUERA C to another FDA approved arthroplasty device at up to 30 centers across the U.S.
BAGUERA C is an MRI compatible disc. Anatomically shaped endplates...
Spineart received Investigational Device Exemption (IDE) approval from FDA to initiate a clinical trial of the BAGUERA® C Cervical Disc Prosthesis. The single-level trial compares BAGUERA C to another FDA approved arthroplasty device at up to 30 centers across the U.S.
BAGUERA C is an MRI compatible disc. Anatomically shaped endplates accommodate patient anatomy and minimize vertebral endplate manipulation. The inner layers of the endplates feature a diamond-like-coating to minimize wear. A load sharing design and the guided mobile nucleus are intended to prevent excessive constraints on the facet joints and adjacent levels.
In 2016, two-year study results indicated that patients treated with the BAGUERA C cervical disc in 1- or 2-level arthroplasty exhibited good mobility at treated and adjacent levels, disc height restoration and evidence of adjacent level preservation.
Jerome Trividic, President of Spineart USA, said, “Thanks to a fruitful collaboration with the FDA, we will be starting patient enrollment in the upcoming months. We are excited to bring BAGUERA C to the United States, after more than a decade of successful patient outcomes outside the U.S.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
